Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer, Gynecologic Oncology, August 2021, Elsevier,
DOI: 10.1016/s0090-8258(21)00657-0.
You can read the full text:
Resources
Contributors
The following have contributed to this page
